This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): FXR Agonist Program (Akarna), AKN083, AKN 083
FXR is a nuclear hormone receptor expressed in the liver, intestine, kidney and fat (adipose) tissue. Akarna is developing a small molecule, non-bile acid FXR agonist that has high affinity, potency and selectivity for FXR.
Allergan and Akarna
In September 2016, Allergan announced that the Company has acquired Akarna Therapeutics for an up-front payment of $50 million, subject to certain adjustments, as well as potential clinical, regulatory and commercial milestone payments related to its lead development compound, AKN-083. In addition to AKN-083, the acquisition also includes a portfolio of additional development-stage FXR compounds.
Additional information available to subscribers only: